Quality of Life Research

, Volume 20, Issue 10, pp 1737–1744

Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia

  • James Signorovitch
  • Andres Brainsky
  • Kelly M. Grotzinger
Article

DOI: 10.1007/s11136-011-9912-9

Cite this article as:
Signorovitch, J., Brainsky, A. & Grotzinger, K.M. Qual Life Res (2011) 20: 1737. doi:10.1007/s11136-011-9912-9

Abstract

Purpose

To assess the validity and reliability of the fatigue subscale of the Functional Assessment of Chronic Illness Therapy (FACIT-F), a 6-item subset from the thrombocytopenia subscale of the Functional Assessment of Cancer Therapy (FACT-Th6) and the Short Form-36 Version 2 (SF-36v2) in 2 clinical trials of the thrombopoietin receptor agonist eltrombopag in chronic immune thrombocytopenia (ITP) patients.

Methods

In the 6-month, RAndomized placebo-controlled ITP Study with Eltrombopag (RAISE; n = 197), the FACIT-F, FACT-Th6, and SF-36v2 were administered at baseline, day 43, weeks 14 and 26, or early withdrawal. In the ongoing open-label extension study, Eltrombopag EXTENDed Dosing Study (EXTEND; n = 154), measures were administered at baseline, at the beginning of each stage, and at permanent discontinuation of study medication.

Results

FACIT-F, FACT-Th6, and SF-36v2 demonstrated acceptable internal consistency reliability (i.e., all Cronbach’s alphas >0.70) and test–retest reliability (all intraclass correlation coefficients >0.70). Construct validity was supported by moderate (0.35 < r < 0.50) to strong (r > 0.50) inter-measure correlations for baseline and change scores. A small to medium magnitude of effect was captured by the FACIT-F and FACT-Th6 among patients who experienced sustained platelet responses.

Conclusions

Results provide support for the validity, reliability, and responsiveness of the FACIT-F, FACT-Th6, and SF-36v2 in chronic ITP patients.

Keywords

Chronic ITP FACIT-F FACT-thrombocytopenia subscale Fatigue SF-36v2 HRQoL Thrombocytopenia Validation studies 

Abbreviations

ANOVA

Analysis of variance

EXTEND

Eltrombopag EXTENDed dosing study

FACIT-F

Fatigue subscale of the Functional Assessment of Chronic Illness Therapy

FACT-Th

Functional Assessment of Cancer Therapy-Thrombocytopenia

HRQoL

Health-related quality of life

ICC

Intraclass correlation coefficient

ITP

Immune thrombocytopenia

LOTA

Last on-treatment assessment

MCS

Mental component summary

MEI-SF

Motivation and Energy Inventory-Short Form

MID

Minimally important difference

PCS

Physical component summary

RAISE

RAndomized placebo-controlled ITP Study with Eltrombopag

SD

Standard deviation

SF-36v2

Medical Outcomes Study Short Form-36 version 2

WHO

World Health Organization

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • James Signorovitch
    • 1
  • Andres Brainsky
    • 2
  • Kelly M. Grotzinger
    • 2
  1. 1.Analysis Group, Inc.BostonUSA
  2. 2.GlaxoSmithKline, Global Health Outcomes, OncologyCollegevilleUSA

Personalised recommendations